Clinical Trial Update: CAR-T-19 Injection in the Treatment of CD19-positive Relapsed/Refractory B-ALL [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating CAR-T-19 therapy for CD19-positive relapsed or refractory B-cell acute lymphoblastic leukemia is currently recruiting. The s…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Acute Lymphoblastic Leukemia

Drugs mentioned

• CAR-T-19 Injection (CD19-directed CAR-T cell therapy)

Snippet

Sponsor: Beijing Yongtai Ruike Biotechnology Company Ltd | Conditions: Relapsed B-cell Acute Lymphoblastic Leukemia, Refractory B-cell Acute Lymphoblastic Leukemia | Phase 2 | Status: RECRUITING